Abstract:INTRODUCTION: Emeritus Editor-in-Chief, Richard Shader, published 2 editorials in 2014 to state that Clinical Therapeutics' would no longer consider simple innovator vs generic bioequivalence studies for publication and would require a rationale for the choice of agents when submitting drug-drug interaction studies for consideration. The intervening decade of developments in this field provides an opportunity to comment on these trends. Lewis Scheiner anchors the subsequent discussion in a "Learn and Confirm" super-structure of thinking about the goals of early development of pharmaceutical agents. Subsequent experience with newer agents that are focused on immunological targets has led to a shift from the simple No Observable Effect Level (NOEL) model to the Minimal Anticipated Biological Effect Level (MABEL) model for biologically focused effects to assess pre-clinical data in guiding the selection of a starting dose for First-in-Human studies.ELEMENTS OF PHASE I STUDIES: The primary tasks of Phase I activities are to describe the pharmacokinetics (determination of absorption, distribution, metabolism, and excretion) and essential pharmacodynamics (the dose correlation with the physiological responses, plus any untoward effects, including idiosyncratic responses) keeping in mind reporting requirements. Other Phase I activities usually conducted later in the development cycle include evaluation of drug interactions with food and other pharmaceutical agents and thorough QT studies.INNOVATIONS: Phase I studies have been evolving in response to the unrelenting pressures to improve access and efficiencies in time, cost, and effort. Changes have been occurring in the characteristics of the participating populations, the starting dose, and shifts in the enrollment schedule to a more flexible, data-driven, adaptive design.ISSUES: Additional issues have gained attention in the recent past, including Phase 0/microdosing, use of Phase I studies explicitly for treatment in the case of oncological products, involvement of Data Safety Monitoring Committees especially for first-in-class molecules, and improved means of optimizing selection of candidate agents for advancement to subsequent stages of development. Of final importance is the need for greater transparency of the presently inaccessible, early development study data maintained in commercial corporate legacy databases. Taken together, these developments and innovations by a broad range of stakeholders point to continuing opportunities for clinical investigators to explore the potential of Phase I studies to contribute to their own specialties.

Design of First-administration Studies in Healthy Man

On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development

Starting Dose Determination Approach for First-in-human Trials

An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics

Phase I Studies: Innovations and Issues

Study on the key steps for the subject medication of phase Ⅰ clinical trials

Discussions on the standardized safety evaluation of new drugs in phase I clinical trials

An Evaluation of First-in-Human Studies for RNA Oligonucleotides

Incorporating Historical Information to Improve Phase I Clinical Trials

Phase I–II Clinical Trial Design: a State-of-the-art Paradigm for Dose Finding

Considerations for Human ADME Strategy and Design Paradigm Shift(s) - An Industry White Paper

Phase 0/microdosing approaches: time for mainstream application in drug development?

Adaptive Dose Modification for Phase I Clinical Trials

AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials

Dose translation between laboratory animals and human in preclinical and clinical phases of drug development

History of Chronic Toxicity and Animal Carcinogenicity Studies for Pharmaceuticals

DEMO: Dose Exploration, Monitoring, and Optimization Using a Biological Mediator for Clinical Outcomes

Design of Animal Experiments in Pharmacological Research

The application of Phase 0 and microtracer approaches in early clinical development: past, present, and future

Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms

Pharmacokinetic-pharmacodynamic Analysis' Role in Design of Phase ROMAN NUMERAL ONE Clinical Trials of Anticoagulant Agents: a Systematic Review